T1	Participants 74 105	patients with allergic rhinitis
T2	Participants 528 575	patients with persistent allergic rhinitis (AR)
T3	Participants 693 826	single-center, randomized, double-blind, placebo-controlled, crossover, two-arm study, 40 patients with persistent AR were randomized
